Sarah Verhoeff

79 PD-1/PD-L1 PET imaging: A novel tool to optimize immunotherapy? 23. Madore J, Vilain RE, Menzies AM, et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti- PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res 2015;28(3):245–53. 24. Ilie M, Long-Mira E, Bence C, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 2016;27(1):147–53. 25. Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate nonredundant immune mechanisms in cancer. Nature 2015;520(7547):373–7. 26. Udall M, Rizzo M, Kenny J, et al. PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. Diagn Pathol 2018;13(1):12. 27. Algenas C, Agaton C, Fagerberg L, et al. Antibody performance in western blot applications is context-dependent. Biotechnol J 2014;9(3):435–45. 28. Mathew M, Safyan RA, Shu CA. PD-L1 as a biomarker in NSCLC: challenges and future directions. Ann Transl Med 2017;5(18):375. 29. Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol 2017;12(2):208–22. 30. Tsao MS, Kerr KM, Kockx M, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol 2018;13(9):1302–11. 31. Stack EC, Foukas PG, Lee PP. Multiplexed tissue biomarker imaging. J Immunother Cancer 2016;4:9. 32. Gorris MAJ, Halilovic A, Rabold K, et al. Eight-color multiplex immunohistochemistry for simultaneous detection of multiple immune checkpoint molecules within the tumor microenvironment. J Immunol 2018;200(1):347–54. 33. Conroy JM, Pabla S, Nesline MK, et al. Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. J Immunother Cancer 2019;7(1):18. 34. Zelba H, Bochem J, Pawelec G, et al. Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy. Cancer Immunol Immunother 2018;67(12):1845–51. 35. Gros A, Robbins PF, Yao X, et al. PD-1 identifies the patient-specific CD8(1) tumor-reactive repertoire infiltrating human tumors. J Clin Invest 2014; 124(5):2246–59. 36. Yue C, Jiang Y, Li P, et al. Dynamic change of PDL1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy. Oncoimmunology 2018;7(7):e1438111. 37. Ilie´ M, Szafer-Glusman E, Hofman V, et al. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. Ann Oncol 2017;29(1):193–9. 38. Cohen JV, Flaherty KT. Response to immune checkpoint antibodies: not all responses are created equal. Clin Cancer Res 2019;25(3):910–1. 39. Lamberts LE, Williams SP, Terwisscha van Scheltinga AG, et al. Antibody positron emission tomography imaging in anticancer drug development. J Clin Oncol 2015;33(13):1491–504. 40. Jauw YW, Menke-van der Houven van Oordt CW, Hoekstra OS, et al. Immuno-positron emission tomography with zirconium-89-labeled monoclonal antibodies in oncology: what can we learn from initial clinical trials? Front Pharmacol 2016;7:131. 41. Broos K, Keyaerts M, Lecocq Q, et al. Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers. Oncotarget 2017;8(26):41932–46. 42. Heskamp S, Hobo W, Molkenboer-Kuenen JD, et al. Noninvasive imaging of tumor PD-L1 expression using radiolabeled anti-PD-L1 antibodies. Cancer Res 2015;75(14):2928–36. 43. Hettich M, Braun F, Bartholoma MD, et al. High-resolution PET imaging with therapeutic antibodybased PD-1/ PD-L1 checkpoint tracers. Theranostics 2016;6(10):1629–40. 44. Heskamp S, Wierstra PJ, Molkenboer-Kuenen JDM, et al. PD-L1 microSPECT/CT imaging for longitudinal monitoring of PD-L1 expression in syngeneic and humanized mouse models for cancer. Cancer Immunol Res 2019;7(1):150–61. 45. Waaijer SJH, Kok IC, Eisses B, et al. Molecular imaging in cancer drug development. J Nucl Med 2018; 59(5):726–32. 46. Kikuchi M, Clump DA, Srivastava RM, et al. Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma. Oncoimmunology 2017;6(7):e1329071. 4